ORIGINAL ARTICLE
Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality
Lu Zhang, Qingya Li, Jing Yang, Penghui Xu, Zhe Xuan, Jianghao Xu, Zekuan Xu
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/9/2022 doi:10.1002/cac2.12386
RESEARCH HIGHLIGHT
Lymphatic metastasis in non-small cell lung cancer: recent discoveries and novel therapeutic targets
Xiayao Diao, Chao Guo, Shanqing Li
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/9/2022 doi:10.1002/cac2.12378
ORIGINAL ARTICLE
Elevated neutrophil extracellular traps by HBV-mediated S100A9-TLR4/RAGE-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma
Xi Zhan, Rui Wu, Xue-Hua Kong, Yan You, Kun He, Xiao-Yu Sun, Yong Huang, Wei-Xian Chen, Liang Duan
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/8/2022 doi:10.1002/cac2.12388
LETTER TO THE EDITOR
Novel endogenous endoplasmic reticulum transmembrane protein SURF4 suppresses cell death by negatively regulating the STING-STAT6 axis in myeloid leukemia
Jayoung Kim, Hansong Lee, Chae Mi Hong, Ji Ho Nam, Hye Ju Yeo, Woo Hyun Cho, Hyung-Sik Kim, Changwan Hong, Yun Hak Kim, Dongjun Lee
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/6/2022 doi:10.1002/cac2.12390
ORIGINAL ARTICLE
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)
Yuankai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Caicun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Yin
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/6/2022 doi:10.1002/cac2.12385
LETTER TO THE EDITOR
Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis
Shengzhe Zhang, Sung Ho Lee, Litong Nie, Yuanjian Huang, Gengyi Zou, Youn-Sang Jung, Sohee Jun, Jie Zhang, Esther M. Lien, Junjie Chen, Jae-Il Park
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/6/2022 doi:10.1002/cac2.12382
LETTER TO THE EDITOR
Detection of piRNA-54265 in human serum: evidence and significance
Dongmei Mai, Ying Ye, Lisha Zhuang, Jian Zheng, Dongxin Lin
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/6/2022 doi:10.1002/cac2.12381
LETTER TO THE EDITOR
Weakened humoral immune responses of inactivated SARS-CoV-2 vaccines in patients with solid tumors
Zhiwei Chen, Peng Zhu, Zuojin Liu, Bin Zhu, Guobing Yin, Jia Ming, Rui Song, Qingbo Pan, Tong Li, Xingwei Jiang, Bing Wang, Shuaibin Liu, Hongxing Cai, Jingjie Wang, Yuling Han, Zijing Lin, Yang Hong, Min Chen, Mingli Peng, Lina Hu, Dachuan Cai, Hong Ren
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/4/2022 doi:10.1002/cac2.12368
LETTER TO THE EDITOR
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer
Yang Zhang, Zi-Xian Wang, Lin Shen, Jin Li, Jing Huang, Wei-Guo Su, Dong-Sheng Zhang, Rui-Hua Xu
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/4/2022 doi:10.1002/cac2.12379
ORIGINAL ARTICLE
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy
Fengying Wu, Tao Jiang, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu
Cancer Communications 2022 42: [ PDF Full-text ] [ HTML Full-text ] [ PubMed] Epub: 11/4/2022 doi:10.1002/cac2.12383
